A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

NCT04293562 · clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
1186
Enrollment
NETWORK
Sponsor class

Conditions

Interventions

Sponsor

Children's Oncology Group

Collaborators